[go: up one dir, main page]

CA1341262C - A new process of the synthesis of 3',4'-anhydrovinblastine, vinblastine and vincristine - Google Patents

A new process of the synthesis of 3',4'-anhydrovinblastine, vinblastine and vincristine Download PDF

Info

Publication number
CA1341262C
CA1341262C CA000543832A CA543832A CA1341262C CA 1341262 C CA1341262 C CA 1341262C CA 000543832 A CA000543832 A CA 000543832A CA 543832 A CA543832 A CA 543832A CA 1341262 C CA1341262 C CA 1341262C
Authority
CA
Canada
Prior art keywords
formula
alkyl
process according
enamine
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000543832A
Other languages
French (fr)
Inventor
Camille A. Boulet
James P. Kutney
Michael Mchugh
Hiroki Tsukamoto
Jun Nakano
Lewis S.L. Choi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Priority to CA000543832A priority Critical patent/CA1341262C/en
Priority to US07/228,821 priority patent/US5047528A/en
Priority to DE3826412A priority patent/DE3826412A1/en
Priority to SE8802813A priority patent/SE467875B/en
Priority to IL8734788A priority patent/IL87347A/en
Priority to CH2974/88A priority patent/CH676711A5/de
Priority to BE8800908A priority patent/BE1003228A4/en
Priority to FR888810637A priority patent/FR2622888B1/en
Priority to NL8801966A priority patent/NL8801966A/en
Priority to IT8821678A priority patent/IT1227155B/en
Priority to AU20512/88A priority patent/AU617342B2/en
Priority to ZA885765A priority patent/ZA885765B/en
Priority to JP63196999A priority patent/JPH0613532B2/en
Priority to CN 88104941 priority patent/CN1027266C/en
Priority to HU884126A priority patent/HU208829B/en
Priority to GB8818765A priority patent/GB2215331B/en
Application granted granted Critical
Publication of CA1341262C publication Critical patent/CA1341262C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04Dimeric indole alkaloids, e.g. vincaleucoblastine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present application relates to a method for producing dimer alkaloid compounds especially of the Catharanthus (Vinca) alkaloid groups and, in particular, for producing the anti-viral, anti-leukemic (antineoplastic) compounds vincristine and vinblastine. Use of selected 1,4-dihydropyridine compounds for the 1,4-reduction of an iminium intermediate to an enamine results in significant increase in the yield of the enamine.
Parameters for the oxidative transformation of enamine to the iminium intermediates and subsequent reduction of the iminium intermediates to vinblastine and leurosidine are disclosed. The overall process, conducted in a one-pot operation, producing vinblastine, leurosidine and 3',4'-dehydrovinblastine is described.

Description

Process for the Synthesis of Vinblastine and Vincristine Field of the Invention The present application relates to a further improvement of a new and improved method for producing dimer alkaloid compounds especially of the Catharanthus (Vinca) alkaloid groups and, in particular, is a further improved method for producing the anti-viral, anti-leukemic (antineoplastic) compounds, vincristine and vinblastine of Formula I.
Iorrr.~rr>
o~~ v.~
frr~r.c) I
The above compound, when R is COOCH3, and Rl is OCH3, is vinblastine (NSC 49482) and when R is COOCH3, and Rl is OCH3 and N1 is N-CHO (N-formyl), vincristine (NSC
67574).
The present series of dimeric alkaloids, including important antitumor agents, are formed from an indole, such as catharanthine (Formula II, R - COOCH3), and a dihydroindole unit, e.g., vindoline (Formula III:), in which ~ 3 4 ~-z s z ._ the halves are linked via a carbon-carbon bond involving an aliphatic center Cl~ in the indole unit and an aromatic carbon C15 in the vindoline portion.
h a C00C 1i II III
Summarv of the Invention The specific improvements in the present applica-tion are set out below.
Firstly, improvement of the novel reduction method, in which conversion of the iminium intermediate (Formula VI) to the enamine (Formula VIII) '~34i2fiZ
_,....
~N_~

~ ~nR = H..., ~.'-' V ~doline ;' ON
Cti3 D ~ " ~t~'~'~'' O~ -CH3 C~i3 R p vi R=CC Ct~!
~o?N a i O I ~ ~ _ .,., _~ _..,-r.' '~'~
I
O
CH30 ~' ~'' Oi -Cti3 CH3 R p VI I I R=C02 CH3 ~~34~2s2 as described in step (e), post, is achieved by the use of various new 1,4-dihydronicotinamides (Formula IX, R2 - R4 -R5 - R6 - H; R3 - CONH2 and R1 may contain different functional groups ;such as aryl, caqrboxylic esters, sugars, carboxylic acid, and carboxylate salt, as represented by Formulae XXVII to XXXII listed in Table 1) and 1,4-dihydropyridine compounds such as Formulae XXXIII and XXXIV.
Of special importance is the presence of electron rich functional groups (e. g., carboxylic esters and carboxylate salts in R1 of Formula IX, capable of coordination with the positively charged iminium intermediate (Formula VI). Such coordination increases both the regioselectivity (1,4-reduction over 1,2-reduction ) and the rate of the reduction of iminium intermediate (Formula VI), leading to an improved yield of the enamine (Formula VIII). Further improvement in the formation of the latter compound is achieved by performing the reduction of iminium intermediate (Formula VI) and maintaining the reaction mixture before any subsequent manipulation at a low temperature (0 to -70°C) preferably below -40°C.
p Rs R3 Re R
z R, IX

'1341262 Specific examples related to the above improve-ments for the synthesis of enamine (Formula VIII) by the 1,4-reduction of the iminium intermediate (Formula VI) are given in the Examples 1-9 (Procedures C to K) . Results of these examples are summarized in Tables 2 and 3. Table 2 indicates reduction procedures (Procedures I and J as in Examples 7 and 8), employing reducing agents Formula XXXI
and Formula XXXII, respectively, afford the best yields of the enamine (Formula VIII). Table 3 shows the effect of temperature in the reduction of iminium intermediate (Formula VI) by the reducing agent Formula XXXII. Lowering the reduction temperature to -40°C (Procedure K(ii) Example 9) resulted in an increase in both the ratio of 1,4-reduction production, enamine (VIII), versus 1,2-reduction product, 3,4-dehydrovinblastine (VII), (4.2:1), as well as the overall yield of the reaction (85~).
The second area of improvement relates to the oxidative transformation of the enamine (Formula VIII) to the iminium intermediate (Formula XVI).
Various parameters for this oxidative transformation have been studied to optimize the yield of vinblastine (Formula I) production.
Table 4 indicates the effect of ferric chloride concentration. Two equivalents of ferric chloride provide the highest yield of vinblastine (I).

13~12f~2 ' _ 'r: E

z - o >

. ~ c w .r G

~rl w an N
v a G ..

r1 .,.1 N ~
r .., .b w I

o .J

G

O M

-.1 v 1~

U

'O

J

U

~ U~~ M

, O
, '_" U

, I Z ~ U

.- . ~

w ~ 'z~' V ' ~' ~ LL

Z1,~~ ~

.
' _ .

O

U

:c v r w a a~ A w 0.
N
~~ I
O a p ~ C~
Z
- ~ .n ~ .n v V U V V
p v _ H _ Z- U Z~
a ~4 a ~4 L1 fir V jp '" ~,i >w.
a.
'~ ,,~ ,~ : O : v U ~o v N ~ n ~ ~ < Z
Z O = t,~ c~, .p O c~ ~c N ~r p _ Z- ~ ~ ~ ~ o 0 v ...~,. ..,~.. 0G ~ ?e b II V v II r r r a N
r1 r~
H h~l N
w Table 2. Effect of Reducing Agent on I,~- vs. 1,2-keduction of Iminiuu ~'i Reduction Procedurel'4 1,4:1,2-Reduction Pzoducts' Yield3 (~) E~ 1:1 75 1:1 60 0.9:1.0 60 v 1:1 40 1.1:1 60 2:1 65 1.5:1 70 1.1:1 65 I 2.3:1 70 J 2.2:1 70 1 Typical Procedure: 100 mg Iminiua VI in 6 ml methanol to which reducing aitenta C-J (1-6 eq.) distolved in 6 ml :ethanol weze added. F~11 details in Fxpeziaental Section.
2 B~ reverse phase HPLC quantitation.
Combined 1,2-reduction (3,4-dehydrovinblastine, VII) + 1,4-reduction tenamiae VIII) products.
4 All of these reactions were co~ucted at 20° C.
Procedures A and B are resented in Canadian p application Serial No.
57,897 and presented here for oar~parison.

~3~fizsz Table 3. Effect of Temperature on 1,4- vs. 1,2-Reduction of Iminiug VI.
Reduction Procedural Teap. (°C) 1,4:1,2-Reduction Products2 Yield3 (t) D 20 2.2:1 70 K (i) -20 3.2:1 80 X (ii) -40 4.2:1 85 1 Typical procedure as in Table 2.

Quantiution by IiPLC.
Cosbined 1,2-reduction (3,4-dehydrovinblastixe, VII) ~ 1,4-reduction (examine VIII) products.

Table ~. Effect of Ferric C~t~loride on Production of Vinblastine (I) f rou Ena~ine VIII3 Amount of FeCi; Orxidation Conditions ! Yield of (Equivalentsl'' (Temp., time) Vinblastine2 p Aizi, Oo C, 5 min 0 I Air , 0 C, 5 min 13.3 l Air C, S min 19.0 , 0 3 Airl, 0 C, 5 min 10.4 pt a rate of 6U ml/min.
B~ revezee-phase HPLC quantiution, after reductive work-up with NaBH4.
3 Ensmine VIII itenerated at -4D° C (Procedure K (ii)).

1341'262 Table 5. Effect of Time of Oxidation on Production of Vinblastine (I) froa Enamine VIII3 Timel (min) a Yield of 2 Vinblastine 1 8.2 15.4 15.5 15.7 45 6.5 Reaction conditions: - 2 eq. ferric chlorine added, air bubbled throu,~ the solution at 60 ~1/min at 0° C.
2 By reverse-phase BpI~C quaatitation aftxr reductive work-up s~ith NaBIi4.
~namine DIII generated at -40° C (Procedure K (ii)).

13412fi2 ~abie E. Effect of Oxidation TemperaturE on Production of t~inbiastine (I) f roa Ena~ine VIII3 TemF., ° CI ~ Yield of 2 vinblastine -40 3..

-23 6.?

0 19.6 20 20.6 16.0 Reaction conditions: 2 eq. ferric chloride added, air bubbled through the solution at 60 sl/~in for 15 mir..
By reverse-phase HPLC quantitation after reductive work-up with NaBP.4.
Enamine generated at -40° C (Procedure K (fi)).

Table 7. Effect of Dilution on Production of Vinblastine (I) frog Enamine vIIT3 Dilution Factorl'4 1 Yield of 2 Vinblastine 1 19.6 25.2 30.1 29.6 50 24.7 1 iteactian conditions: 2 eq. ferric chloride added, air bubbled through the solution at 60 slain for 15 :in. at 0° C.
2 By reverse-phase xPI~C quantitation after reductive work-up with NaBIi4.
Enamine Generated at -40° C (Procedure R (ii)).
~' Dilution Factor 1 ~ 100 ~g Isinium 'VI in 6 :1 sethanol to ~rhich reducing agent Formula III (6 aq.) in 6 st2 ~ethaaol vas added.
(Total voluae ~ 1~ ~1) Dilution Factor 5 ~ Total voltme of b0 ml, etc.

13412fi2 Table 5 indicates results relating to yield of vinblastine versus time of oxidation. The maximum yield of vinblastine (I) is reached after 5 to 20 minutes of aeration in the presence of 2 equivalents of ferric chloride.
Table 6 shows the results of various oxidation temperatures, in the presence of two equivalents of ferric chloride, on the yield of vinblastine (I). The temperature range of 0°C to 20°C provides the highest yield of vinblastine (I) after a reductive work-up with NaBH4, as quantified by reverse-phase HPLC.
The effect of dilution of the enamine (VIII) solution on the production of vinblastine (I), is indicated in Table 7. A dilution factor of 10 to 20 on the enamine (VIII) solution before aeration in the presence of ferric chloride (2 equivalents) at 0°C, affords the best yield of vinblastine (I) as quantified by reverse-phase HPLC after reductive work-up with NaBH4.
In summary, the specific improvements in the present application as they relate to the oxidative trans-formation of the enamine (VIII), involve the dilution (5 to 50 folds) of the enamine (Formula VIII) solution, obtained in the above reduction of iminium intermediate (Formula VI), by the same solvent used in the reduction. For practical purposes, the preferred dilution factor is usually in the range of 8 to 12 folds. The above procedure is conducted at a low temperature (0°C to -70°C), preferably below -40°C and under cover with inert conditions such as argon or an inert gas of Group Zero of the Periodic Table (nitrogen, helium, neon, etc.). After this dilution process, the oxidative transformation of the enamine (Formula VIII) can be carried out as described above (aeration at 60 ml/min for 15 min at 0°C in the presence of ferric chloride (2 eq.)) to afford the corresponding iminium intermediates (Formula XVI).
OOf l N...
- _H_ -~.- t7-r H ,.:
_~ I
vindof ine O OH
CH30 ~ ~O~ "CH3 Formula RVI
The third area of improvement relates to the reduction of iminium intermediates (Formula XVI) by alkali metal borohydride (NaBH4, KBH4, LibH4, etc.) to vinblastine (Formula I) and/or leurosidine (Formula XXXV). The iminium intermediates (Formula XVI and Formula XVIa) produced from the oxidative transformation of enamine (Formula VIII) are reduced by the addition of alkali metal borohydride at low temperature (4°C to -20°C), preferably at 0°C. The reduc-tion is conducted at pH lower than 8.5 and preferably at 7.5 to 8. The total reaction mixture is then concentrated in vacuo at low temperature (0°C to 10°C) before extraction and isolation of alkaloid products.

1 347 2fi 2 H
I R N ~ ~ ~t oo~
O RN-H'w~--~ I 1 _H_.-w ~"'~
I
off CH30 N~O~ -CH3 O OH
CH3 R 0 CH3 0 ~~ Oy'CH3 R=COy~i3 CH3~ 0 R=C0yCH3 Formula XXXV (Leurosidine) Formula XVIa For practical purposes, all the above improvements can be incorporated, as indicated, directly into the overall process conducted in a one-pot operation from the indole unit (Formulas II, XXII or XXIII) and the dihydroindole unit (Formula XXI, R - H) to the final products of Formula XXI.
Isolation of the various intermediates (Formulas XXIV, VI, VIII and XVI) is omitted as summarized in Scheme 1.
In summary, the present method is applicable to the production of dimer products from catharanthine and dihydrocatharanthine with vindoline as starting materials and phenyl, alkyl and amide derivatives embraced by the following formulas:

Scneme 1. Optimum procedure for one-pot process - vinblastine from catharanthine and vindoline.
D
r ca~c~
XXtV
~C~3CO~Z O l 1 _60 o C !i 0 t OH ~ _Cti~
C, yr OKs o (r CONIiZ
l t 3 c t.Z-Reduction f Enamine Anhydrovinbls~tme R~tso t.Z:1 1 34i 262 Scneu~_ : - cor,:inue~
h' ..
J
CH~O ~''~''~'!~~-Ct~
R ~ Gp2Ct~3 vllt FeCI 2 a uiv.), 0° C
Air. ~~ mi9min. !5 min Dilution Factor 10 00 ff ~ ooH
CiisO ~~ ~~~_C~~
XVI
XVIe NvBii~ N~Bfix _C+~i X341262_ Formula XXI is as pictured and in that formula alk represents a lower alkyl group of Cl-C6 and preferably Cl-C3; aryl is mono-aryl such as benyzl, styryl, and xylyl; Rl is a member of the group consisting of hydrogen, alk, CHO
and COR5 where R5 is alkyl or aryl; R2 and R3 are members of the group consisting of hydrogen and -CO-alk; R4 is a member of the group consisting of COO-alk, CONH-NH2, CONH2, CONHR6, and CON(R6)2 where R6 is alkyl; Z is a member of the group consisting of -CH2-CH2- and -CH-CH- and R is a member of the indole family represented by Formula XXII
where R~ is a member of the group consisting of hydrogen, or COO-alk; R8 is a member of the group consisting of hydrogen, OH, O-alk, OCO-alk or alkyl; R9 is a member of the group consisting of hydrogen, OH, O-alk, OCO-alk, or alk; R10 is a member of the group consisting of hydrogen, OH, O-alk, OCO-alk, or Formula XXIII where R11 is a member of the group consisting of hydrogen or COO-alk; R12 is a member consisting of alkyl.
SEecific Description of the Invention This invention is specifically a process for the production of compounds represented by the following formulas:
s XXI
n s' o-~z iO n ~ i 1W' 13412fi2 xIi x XXIII
G
wherein in Formula XXI
Alkyl = CH3 or (CH2)nXH3 where n=1-5 Rl - CH3 or CHO
R2 - H or CO-alk R4 - COO-alk or CONR13R14 where R13 and R14 can be any member of the group consisting of hydrogen, alkyl, substituted alkyl, aryl or substituted aryl functions Z - -CH=CH- or -CH2-CH2-R - Formula XXII or XXIII
R~ - or COO-alk H

R8 - OH, O-alk, OCO-alk or alkyl H, R~ - OH, O-alk, OCO-alk or alkyl H, R1~ - OH, O-alk, OCO-alk H, R11 - or COO-alk H

R12 - or alkyl H

wherein the process a dimer derived is for the synthesis of from an indole unit of the natural Iboga alkaloid family containing an a dihydroindole aza bicyclo-octane portion and 13~~~62 unit of the natural Aspidosperma and Vinca alkaloid families, the stereochemistry of the carbon-carbon linkage between these two units being identical with that of vinblastine which consists of (a) forming an N-oxide intermediate in the cold at a temperature of -70°C to +40°C from said indole unit by oxidizing the bridge nitrogen and without isolating said intermediate;
(b) treating said 2~-oxide indole intermediate in the presence of one member of the group consisting of acetic anhydride, halogenated acetic anhydride, and acetyl chloride to effect a Polonovski-type fragmentation reaction;
(c) without isolating the product of step (b), coupling said reaction product with a dihydroindole unit in the presence of acetic anhydride, halogenated acetic anhydride, and acetyl chloride at a low temperature of about -70°C to +40°C under inert conditions;
(d) the product of step (c) is solated by solvent evaporation preferably at low temperature in the range of -20°C to 0°C;
(e) the product of step (d) is reduced by 1,4-dihydropyridine compounds represented by Formula IX
H Rw R R, IX
~Z
Ri where R3 and R5 in Formula IX are carboxylic esters (COO-alk) and Rl, R2, R4 and R6 are members of the group consisting of H, alkyl, aryl (Hantzch ester series) or tv-substituted 1,4-dihydronicotinamides where R1 is a substituted alkyl or substituted aryl function, for example, benzyl, and R3 is CONR~RB where R~ and R8 is one member of the group consisting of hydrogen, alkyl or aryl function;
(f) the product of step (e), an enamine, Formula VIII, is isolated by solvent evaporation, preferably at low temperature in the range of -20°C to 0°C;
(g) the product of step (e), a solution of enamine VIII, is diluted (5 to 50 folds) by the same solvent employed, preferably in the range of 8 to 12 folds at a low temperature (0°C to -70°C), preferably below -40°C;
(h) the enamine obtained in step (f) or the enamine solution obtained in step (g) is used to prepare iminium intermediates, Formula XVI or XVIa, by a number of oxidative processes including:
(1) controlled aeration/oxygenation in which a solution of the enamine is stirred in open air or with a stream of air/oxygen bubbled through the solution;
(2) as in (1) but with the addition of a metal ion;
(3) as in (1) but with the addition of a flavin coenzyme, as represented by Formula XII, to generate, in situ, the corresponding 1,5-dihydroflavin coenzyme, as represented by Formula XIII;
(4) as in (1) but with the addition of hydrogen peroxide and/or hydroperoxides as represented by the Formula R-OOH where R is alkyl or aryl (i) the product, an iminium intermediate or iminium intermediates obtained in step (h) is isolated by sovlent evaporation, preferably at low temperature in the range of -20°C to 0°C;
(j) the product obtained in step (i) or the iminium intermediate solution obtained in step (h) is converted to the target compounds of Formula XXI, for which vinblastine and vincristine are examples and leurosidine (Formula XXXV) by reduction with alkali metal borohydride (NaBH4, KBH4, LiBH4) in suitable solvents (organic and/or aqueous) as used in the oxidative processes of step (h).
Of special importance is the presence of electron rich functional groups (e.g., caqrboxylic esters and carboxylate salts) in R1 of Formula IX, capable of coordination with the positively charged iminium intermediate (Formula VI). Some examples of these 1,4-dihydropyridine compounds are given in Table 1 (e. g., Formulas XXXI and XXXII). Such coordination increases both the regioselectivity (1,4-reduction over 1,2-reduction) and the rate of the reduction of iminium intermediate (Formula VI), leading to an improved yield of the enamine (Formula VIII).
The reduction is conducted under an inert atmosphere at -60°C to +60°C but preferably in the temperature range -20°C to -40°C. The solvents employed are alcohols, acetonitrile or higher members of this series, dimetheyl sulfoxide, dimethylformamide, various ethers such as dioxane and tetrahydrofuran, and chlorinated hydrocarbons.
The oxidative processes in step (h) (1)-(4) are conducted in organic solvents such as alcohols, acetonitrile or higher members of this series, dimethyl sulfoxide, dimethylformamide, various ethers such as dioxane, tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene, etc. An aqueous buffer (e. g., phosphate, Tris-HC1, MES buffers) at pH 5-9, but preferably in the range of 6-8, can be used as co-solvent. The reaction temperature may vary from -60°C to +60°C.
Of special importance is the presence of electron rich functional groups (e.g., caqrboxylic esters and carboxylate salts) in R1 of Formula IX, capable of coordination with the positively charged iminium intermediate (Formula VI). Some examples of these 1,4-dihydropyridine compounds are given in Table 1 (e. g., Formulas XXXI and XXXII). Such coordination increases both the regioselectivity (1,4-reduction over 1,2-reduction) and the rate of the reduction of iminium intermediate (Formula VI), leading to an improved yield of the enamine (Formula VIII).
The reduction is conducted under an inert atmosphere at -60°C to +60°C, but preferably in the temperture range of -20°C to -40°C. The solvents employed are alcohols, acetonitrile or higher members of this series, dimethyl sulfoxide, dimethylformamide, various ethers such as dioxane and tetrahydrofuran and chlorinated hydrocarbons.
The product of step (e) above, an enamine, Formula VIII, is isolated by solvent evaporation, preferably at low temperature in the range of -20°C to 0°C.
The process of this invention also prepares an ~3~~2sz enamine and oxidizes said enamine to the iminium inter-mediate (Formula XVI and XVIa) by a number of oxidative processes including:
(a) controlled aeration/oxygenation in which a solution of the enamine is stirred in open air with a stream of air/oxygen bubbled through the solution;
(b) as in step (h)(1) but with the addition of a ferric chloride;
( c ) as in step ( h ) ( 1 ) but with the addition of a flavin coenzyme, as represented by Formula XII:
..OH
1~ ~1~~0 XII
w to generate, in situ, the corresponding 1,5-dihydroflavin coenzyme, as represented by Formula XIII
XIII
H
i NN
f1 The oxidative processes are conducted in organic solvents such as alcohols, acetonitrile or higher members of this series, dimethyl sulfoxide, dimethylforman;ide, ethers such as dioxane, tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene, etc.
EXAMPLES
The following examples (Examples 1 - 8) were conducted at 20°C.
Example 1 Reduction of Iminium Intermediate (Formula VI) with 1-Diphenylmethyl (-1,4-dihydronicotinamide (Formula IX, R1 -Biphenyl methyl; R2 = R4 = R5 = R6 = H; R3 = CONH2) (Formula XXVII) - Synthesis of Enamine (Formula VIII) - Procedure C) To a stirred solution of iminium intermediate (VI, 100 mg) in degassed ethanol (6 ml) was added 1-diphenylmethyl-1,4-dihydronicotinamide (Formula XXVII) (76 mg, 2.5 equivalents) in methanol (6 ml) under a positive atmosphere of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 60 min. After this, reverse phase HPLC analysis (Waters Radial-Pak C18 or CtJ cartridge, methanol-H20-Et3N as solvent system) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 0.9:1 (60$
yield).
Example 2 Reduction of Iminium Intermediate (Formula VI) with 1-Benzyl-3-cyano-1,4-dihydropyridine (Formula IX, Rl - benzyl;
R2 = R4 = R5 = R6 = H; R3 = CN) (Formula XXXIII) - Synthesis of Enamine (Formula VIII) - (Procedure D).

To a stirred solution of iminium intermediate (VI, 100 mg) in degassed methanol (6 ml) was added 1-benzyl-3-cyano-1,4-dihydropyridine (Formula XXXIII) (206 mg, 10 equivalents) in methanol (10 ml) under a positive atmosphere of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 60 min. After this, reverse phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 1:1 (40~ yield).
Example 3 Reduction of Iminium Intermediate (Formula VI) with 1-Benzyl-1,4-dihydronicotinyl-(2'-carbamoyl-pyrrolidinyl)-amide (Formula IX, Rl = benzyl; R2 - R4 - R5 - R6 - H; R3 -(2' carbamoyl-pyrrolidinyl) carbonyl) (Formula XXXIV) -Synthesis of Enamine VIII) - (Procedure E).
To a stirred solution of iminium intermediate (VI, 100 mg) in degassed methanol (6 ml) was added 1-benzyl-1,4-dihydronicotinyl-(2'-carbamoyl-pyrrolidinyl)-amide (Formula XXXIV) (163 mg, 5 equivalents) in methanol (5 ml) under a positive pressure of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 3U min. After this, reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 1.1:1 (60~
yield).
Example 4 Reduction of Iminium Intermediate (Formula VI) with 1,4-Dihydro-1-(1-methoxycarbonyl isobutyl)-nicotinamide (Formula IX, R1 - 1-methoxycarbonyl isobutyl; R~ - R4 - R5 - R6 - H;
R3 - CONH2) (Formula XXVIII) - Synthesis of Enamine (Formula VIII) - (Procedure F) To a stirred solution of iminium intermediate (VI, 100 mg) in degassed methanol (6 ml) was added 1,4-dihydro-1-(1-methoxy carbonylisobutyl)-nicotinamide (Formula XXVIII) (150 mg, 6 equivalents) in methanol (6 ml) under a positive pressure of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 30 min. After this, reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 2:1 (65~
yield).
Example 5 Reduction of Iminium Intermediate (Formula VI) with 1-(2',3',4',6'-Tetraacetyl-(beta)-D-glucopyranosidyl)-1,4-dihydronicotinamide (Formula IX, R1 - (2',3',4',6'-Tetra-acetyl-(beta)-D-glucopyranosidyl; R2 - R4 - R5 - R6 - H; R3 - CONH2) (Formula XXIX) - Synthesis of Enamine (Formula VIII) - (Procedure G) To a stirred solution of iminium intermediate (VI, 100 mg) in degassed methanol (6 ml) ws added 1-(2',3',4',6'-tetra-acetyl-(beta)-D-glycopyranosidyl)-1,4-dihydronicotin-amide (Formula XXIX) (238 mg, 5 equivalents) in methanol (10 ml) under a positive atmosphere of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 60 min. After this, reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 1.5:1 (70~ yield).
Example 6 Reduction of Iminium Intermediate (Formula VI) with 1,4-Di-hydro-1-(2'-methoxycarbonyl isopropyl)-nicotinamide (Formula IX, Rl - 2' -methox;~ carbonylisopropyl; R2 - R4 - R5 - R6 -H; R3 = CONH2) (Formula XXX) - Synthesis of Enamine (Formula VIII) - (Procedure H) To a stirred solution of iminium intermediate (VI, 100 mg) in degassed methanol (6 ml) was added 1,4-dihydro-1-(2'-methoxy-carbonylisopropyl)-nicotinamide (Formula XXX) (82 mg, 3.5 equivalents) in methanol (7 ml) under a positive atmosphere of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 30 min. After this, reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of l.l:l (65~
yield).
Example 7 Reduction of Iminium Intermediate (Formula VI) with 1,4-Dihydro-1-(1',2'-dimethoxy carbonyl ethyl 1, R2 - R4 - R5 -R6 - H; R3 - CONH2) (Formula XXXI) - Synthesis of Enamine (Formula VIII) - Procedure I) To a solution of iminium intermediate (VI, 100 mg) in degassed methanol (6 ml) was added 1,4-dihydro-1-(1',2'-dimethoxy carbonyl ethyl)-nicotinamide (Formula XXXI) (148 mg, 5 equivalents) in methanol (10 ml) under a positive atmosphere of argon, the reducing agent being added i 341 2s 2 portionwise at the rate cf 1 equivalent each 30 min. After this, reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 1.1:1 (70~
yield).
Example 8 Reduction of Iminium Intermediate (Formula VI) with 1,4-Dihydro-1-(sodium-isobutyl-1-carboxylate)-nicotinamide (Formula IV, Rl - sodium-isobutyl-1-carboxylate; R2 - R4 -R5 - R6 - H; R3 - CONH2) (Formula XXXII) - Synthesis of Enamine (Formula VIII) - (Procedure J) To a solution of iminium intermediaqte (VI, 100 mg) in degassed methanol (6 ml) wqs added 1,4-dihydro-1-(sodium-isobutyl-1-carboxylate)-nicotinamide (Formula XXXII) (130 mg, 5 equivalents) in methanol (6 ml) under a positive atmosphere of argon, the reducing agent being added portionwise at the rate of 1 equivalent each 30 min. After this, reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 2.2:1 (70~
yield).
Example 9 Reduction of Iminium Intermediate (Formula VI) with 1,4-Dihydro-1-(sodium-isobutyl-1-carboxylate)-nicotinamide (Formula IX, R1 - sodium-isobutyl-1-carboxylate; R2 - R4 -R5 - R6 - H; R3 - CONH2) (Formula XXXII) at low temperature - Synthesis of Enamine (Formula VIII) (Procedure K) (i) To a solution of iminium intermediate (VI, 100 13~12fit mg) in degassed methanol (6 ml) at -20°C was added 1,4-dihydro-1-(sodium-isobutyl-1-carboxylate)-nicotinamide (Formula XXXII) (155 mg, 6 equivalents) in methanol (6 ml) under a positive atmosphere of argon, the reducing agent being added in one portion. After 45 min. at this temperature reverse-phase HPLC analysis (as described above) indicated, among other products, formation of enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 3.2:1 (80$ yield).
(ii) Carrying out the reaction above at -40°C
gave, after 60 minutes, enamine (VIII) and 3',4'-dehydrovinblastine (VII) in a ratio of 4.2:1 (85$ yield).
Example 10 Synthesis of Vinblastine (Formula I) by Oxidation of Enamine (Formula VIII) to Iminium Intermediate (Formula XVI) with Air in the Presence of Ferric Chloride at High Dilution.
(Method 5) The solution containing the enamine (VIII), (Procedure K (ii)) obtained from the iminium intermediate (VI, 200 mg) was diluted five-fold with methanol before oxidation (total vol.: 120 ml). Ferric chloride (75 mg, 2 equivalents) was then added, and air bubbled through the solution, at 0°C, for 20 min. Sodium borohydride (200 mg) was added, and the solution concentration in vacuo before adding water (100 ml) and extracting with ethyl acetate (3 x 200 ml). The combined organic extract was dried over Na2S04 and the solvent evaporated in vacuo. The crude product was purified by column chromatography (silica gel, TLC grade, 15 g). Elution with ether: chloroform (10:7) gave 3',4'-de-hydrovinblastine (VII, 18 mg, 11~). Further elution with ether: chloroform: methanol (10:7:0.5) gave vinblastine (I, 62 mg, 37$).
Example 11 One-Pot Conversion of Catharanthine (Formula II) and Vindoline (Formula III) to Vinblastine (Formula I) and Leurosidine (Formula XXXV) - Overall Procedure To a solution of catharanthine (II, 500 mg, 1.5 mmol) in dry dichloromethane (4.5 ml) at -15°C under a positive atmosphere of argon was added m-chloroperbenzoic acid (330 mg, 1.9 mmol) in one portion, and the mixture stirred at -10 to -15°C for 5 minutes. After this time the reaction mixture was cooled to -40°C and a solution of vindoline (III, 450 mg, 1 mmol) in dry dichloromethane (1 ml) was added, followed immediately by trifluoroacetic anhydride (1 ml, 7.1 mmol). After 2 h at -60°C volatiles were removed in vacuo (high vacuum pump) and dry, degassed methanol (12 ml) added after flushing the system with argon.
The resulting orange solution was cooled to -40°C and a solution of 1,4-dihydro-1-(sodium-isobutyl-1-carboxylate)-nicotinamide (Formula XXXII) (1.5 g, 6 mmol) in dry degassed methanol (12 ml) was added under a positive atmosphere of argon. After reduction was complete (by reverse-phase HPLC
monitoring), cold methanol (about 300 ml) was added, keeping the temperature of the solutionn between -5 and 0°C. Ferric chloride (330 mg, 2 mmol) was then added and dry air bubbled through the solution at a rate of 60 ml/min for a period of 20 min. Sodium borohydride (1 g) was added and the solution 1 3~~ 2s 2 concentrated in vacuo (water aspirator) before adding water (100 ml) and extracting with ethyl acetate (3 X 150 ml).
The combined organic extract was dried over Na2S04 and the solvent evaporated in vacuo to give the crude product which was purified by chromatography as previously described to give 3',4'-dehydrovinblastine (VIII, 95 mg, 12~), vin-blastine (I, 315 mg, 39~) and leurosidine (XXXV, 130 mg, 16$).

Claims (16)

1. A process for the production of dimer alkaloid compounds comprising the steps of:
(a) oxidizing an indole unit having a bridge nitrogen and being represented by the following formula:

wherein R represents hydrogen or COO-alkyl, said oxidation being carried out in the cold, at a temperature from about -77 °C to about +40 °C, thereby oxidizing the bridge nitrogen of said indole unit and forming an N-oxide derivative as represented by the following formula:

wherein R is the same as above, and without isolating said derivative;
(b) treating said N-oxide derivative in the presence of at least one member selected from the group consisting of acetic anhydride, halogenated acetic anhydride, and acetyl chloride, to effect a Polonovski-type fragmentation reaction;

(c) without isolating the product of step (b), stereospecifically coupling said product of step (b) with a dihydroindole unit represented by the formula:

said coupling being conducted in the presence of at least one member selected from the group consisting of acetic anhydride, halogenated acetic anhydride, and acetyl chloride at a low temperature of about -70°C to about +40°C, under inert conditions, to form a first iminium intermediate, represented by the formula:

(d) reducing said first iminium intermediate by reaction with a 1,4-dihydropyridine compound, represented by the formula:

wherein R1 is H, alkyl, substituted alkyl, aryl, substituted aryl and sugar units;
R2, R4 and R6, independently, are H, alkyl or aryl;
R3 is cyano, CONR7R8 wherein R7 and R8 independently may be H, alkyl, aryl, or taken together, R7 and R8 can form a ring structure containing up to four carbon atoms, said ring structure may further be substituted by CONR9R10, wherein R9 and R10 are H or alkyl; and R5 may be H, alkyl, carboxylate and salts thereof, and aryl;

with the proviso that, when R3 is CONH2, and R2, R4, R5 and R6 are H, then R1 is other than benzyl;

thereby forming an enamine intermediate, represented by the following formula:

(e) transforming said enamine intermediates obtained in step (d) by oxidation under controlled aeration conditions in the presence of ferric chloride to a second iminium intermediate, as represented by the following formula:

wherein:
R x is OOH or C2H5 and R y is OOH or C2H5, with the proviso that R x and R y cannot be the same; and (f) reducing the second iminium intermediate obtained in step (e) to form said dimer alkaloid compounds, represented by the formula:

wherein: R x and R y are OH or C2H5, with the proviso that R x and R y cannot be the same.
2. The process according to claim 1, wherein R1 is arylalkyl, diarylalkyl, alkoxycarbonylalkyl, dialkoxycarbonylalkyl, alkali metal salts thereof, and sugar units.
3. The process according to claim 1 or 2, wherein the 1,4,dihydropyridine reducing agent used in step (d) is selected from the group consisting of:
1-diphenylmethyl-(1,4-dihydronicotinamide);

1-benzyl-3-cyano-1,4-dihydropyridine;
1-benzyl-1,4-dihydronicotinyl-(2'-carbamoyl-pyrrolidinyl)-amide;
1,4-dihydro-1-(1-methyoxycarbonyl isobutyl)-nicotinamide;
1- (2', 3',4', 6'-tetraacetyl-(beta)-D-glucopyranosidyl-1,4-dihydronicotinamide;
1,4-dihydro-1-(2'-methoxycarbonyl isopropyl)-nicotinamide;
1,4-dihydro-1-(1',2'-dimethoxy carbonyl ethyl)-nicotinamide; and 1,4-dihydro-1- (sodium-isobutyl-1-carboxylate)-nicotinamide.
4. The process according to anyone of claims 1 to 3, further including the step of diluting said enamine obtained in step (d) by a factor of 5 to 50 fold with a solvent prior to performing step (e).
5. The process according to anyone of claims 1 to 4, wherein the oxidative transformation step (e) is conducted at a pH in the range of 6-8.
6. The process according to anyone of claims 1 to 5, wherein about two equivalents of ferric chloride are employed in step (e).
7. The process according to anyone of claims 1 to 6, wherein the time of aeration in the oxidation transformation step (e) is from about five to about twenty minutes.
8. The process according to anyone of claims 1 to 7, wherein the oxidative transformation step (e) is conducted at a temperature in the range from about 0°C to about 20°C.
9. The process according to claim 4, wherein said enamine obtained in step (d) is diluted from about 5 to about 20 fold with a solvent, prior to performing step (e).
10. The process according to claim 9, wherein said enamine is diluted 8 to 12 fold.
11. A process according to anyone of claims 1-10, wherein R is COO-alky and alkyl group is C1-C3.
12. A process according to claim 11, wherein alkyl group is CH3.
13. A process according to claim 12, wherein in the intermediate obtained in step (e), R x is OH and R y is CH2CH3 to obtain vinblastine and recovering said vinblastine.
14. A process according to claim 12, wherein in the intermediate obtained in step (e) R x is CH2CH3 and R y is OH to obtain leurosidine and recovering said leurosidine.
15. A process according to claim 12, further comprising the step of oxidizing said vinblastine to obtain vincristine, and isolating said vincristine.
16. A process for the production of 3',4'-anhydrovinblastine comprising the steps of:
(a) oxidizing catharanthine, said oxidation being carried out in the cold, at a temperature from about -77°C. to about +40°C, thereby oxidizing the bridge nitrogen of said catharanthine and forming an N-oxide derivative, and without isolating said derivative;
(b) treating said N-oxide derivative in the presence at least of one member selected from the group consisting of acetic anhydride, halogenated acetic anhydride, and acetyl chloride, to effect a Polonovske-type fragmentation reaction;
(c) without isolating the product of step (a), stereospecifically coupling said product of step (b) with vindoline said coupling being conducted in the presence of at least one member selected from the group consisting of acetic anhydride, halogenated acetic anhydride, and acetyl chloride at a low temperature of about -70°C to about +40°C, under inert conditions, to form a first iminium intermediate, represented by the formula:

(d) reducing said first iminium intermediate by reaction with a 1,4-dihydropyridine compound, represented by the formula:

wherein R1 is H, alkyl, arylalkyl, diarylalkyl, alkoxy, alkoxycarbonylalkyl, dialkoxycarbonylalkyl, alkali metal salts therof, carboxylate ester, aryl, and sugar units;
R2, R4 and R6, independently, are H, alkyl or aryl;
R3 is cyano, CONR7R8 wherein R7 and R8 independently may be H, alkyl, aryl, or taken together, R7 and R8 can form a ring structure containing up to four carbon atoms, said ring structure may further be substituted by CONR9R10, wherein R9 and R10 are H or alkyl; and R5 may be H, alkyl, carboxylate and salts thereof, and aryl;
with the proviso that, when R3 is CONH2 ,and R2, R4, R5 and R6 are H, then R1 is other than benzyl.
CA000543832A 1987-01-22 1987-08-06 A new process of the synthesis of 3',4'-anhydrovinblastine, vinblastine and vincristine Expired - Fee Related CA1341262C (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CA000543832A CA1341262C (en) 1987-08-06 1987-08-06 A new process of the synthesis of 3',4'-anhydrovinblastine, vinblastine and vincristine
US07/228,821 US5047528A (en) 1987-01-22 1988-08-02 Process of synthesis of vinblastine and vincristine
DE3826412A DE3826412A1 (en) 1987-08-06 1988-08-03 METHOD FOR THE SYNTHESIS OF VINBLASTIN AND VINCRISTIN
SE8802813A SE467875B (en) 1987-08-06 1988-08-03 PROCEDURES FOR THE PREPARATION OF THE VINBLASTIN AND THE VINE CRYSTAL.
IL8734788A IL87347A (en) 1987-08-06 1988-08-04 Process for the synthesis of vinblastine and vincristine
NL8801966A NL8801966A (en) 1987-08-06 1988-08-05 PROCESS FOR THE PREPARATION OF VINBLASTINE AND VINCRISTINE.
BE8800908A BE1003228A4 (en) 1987-08-06 1988-08-05 PROCESS FOR THE SYNTHESIS OF VINBLASTINE AND VINCRISTINE
FR888810637A FR2622888B1 (en) 1987-01-22 1988-08-05 IMPROVED PROCESS FOR THE SYNTHESIS OF VINBLASTINE AND VINCRISTINE
CH2974/88A CH676711A5 (en) 1987-08-06 1988-08-05
IT8821678A IT1227155B (en) 1987-08-06 1988-08-05 VINBLASTIN AND VINCRISTINE SYNTHESIS PROCEDURE.
AU20512/88A AU617342B2 (en) 1987-01-22 1988-08-05 Process for the synthesis of dimer alkaloid compounds
ZA885765A ZA885765B (en) 1987-08-06 1988-08-05 Process for the synthesis of vinblastine and vincristine
CN 88104941 CN1027266C (en) 1987-08-06 1988-08-06 Process for synthesis of dimer alkaloid compounds
JP63196999A JPH0613532B2 (en) 1987-08-06 1988-08-06 How to generate dimers
HU884126A HU208829B (en) 1987-08-06 1988-08-08 Process for synthetizing dimeric alkaloid compounds
GB8818765A GB2215331B (en) 1987-08-06 1988-08-08 Improvements in or relating to the synthesis of vinblastine and vincristine and related compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA000543832A CA1341262C (en) 1987-08-06 1987-08-06 A new process of the synthesis of 3',4'-anhydrovinblastine, vinblastine and vincristine

Publications (1)

Publication Number Publication Date
CA1341262C true CA1341262C (en) 2001-06-26

Family

ID=4136214

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000543832A Expired - Fee Related CA1341262C (en) 1987-01-22 1987-08-06 A new process of the synthesis of 3',4'-anhydrovinblastine, vinblastine and vincristine

Country Status (12)

Country Link
JP (1) JPH0613532B2 (en)
AU (1) AU617342B2 (en)
BE (1) BE1003228A4 (en)
CA (1) CA1341262C (en)
CH (1) CH676711A5 (en)
DE (1) DE3826412A1 (en)
GB (1) GB2215331B (en)
HU (1) HU208829B (en)
IT (1) IT1227155B (en)
NL (1) NL8801966A (en)
SE (1) SE467875B (en)
ZA (1) ZA885765B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047528A (en) * 1987-01-22 1991-09-10 University Of Bristish Columbia Process of synthesis of vinblastine and vincristine
USRE37449E1 (en) 1987-02-06 2001-11-13 University Of British Columbia Process of synthesis of 3′,4′-anhydrovinblastine, vinblastine and vincristine
US5432279A (en) * 1989-03-04 1995-07-11 Mitsui Petrochemical Industries, Inc. Process for the preparation of binary indole alkaloids
ATE182140T1 (en) * 1990-11-30 1999-07-15 Fujirebio Kk OPTICALLY ACTIVE 1,4-DIHYDROPYRIDINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
JP3010151U (en) * 1994-04-26 1995-04-25 スミ子 片山 A cylindrical tableware storage case with a notch.
FR2779146B1 (en) * 1998-06-02 2002-01-18 Roowin NOVEL VINCA-ALKALOIDE DERIVATIVES AND PREPARATION METHODS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4279817A (en) * 1975-05-30 1981-07-21 The United States Of America As Represented By The Department Of Health & Human Services Method for producing dimer alkaloids
HU195513B (en) * 1984-10-16 1988-05-30 Richter Gedeon Vegyeszet Process for producing stable solutions of alkaloides with bis-indole skeleton
EP0215058A1 (en) * 1985-03-12 1987-03-25 The University Of Vermont And State Agricultural College Synthesis of vinblastine and vincristine type compounds
CA1341261C (en) * 1987-01-22 2001-06-26 James P. Kutney Process for the synthesis of 3',4'-anhydrovinblastine, vinblastine and vincristine

Also Published As

Publication number Publication date
IT1227155B (en) 1991-03-19
JPH01151590A (en) 1989-06-14
GB8818765D0 (en) 1988-09-07
IT8821678A0 (en) 1988-08-05
AU2051288A (en) 1989-02-09
CH676711A5 (en) 1991-02-28
GB2215331B (en) 1992-01-02
HUT50351A (en) 1990-01-29
BE1003228A4 (en) 1992-02-04
JPH0613532B2 (en) 1994-02-23
SE467875B (en) 1992-09-28
SE8802813L (en) 1989-02-07
HU208829B (en) 1994-01-28
ZA885765B (en) 1989-09-27
SE8802813D0 (en) 1988-08-03
NL8801966A (en) 1989-03-01
GB2215331A (en) 1989-09-20
DE3826412A1 (en) 1989-02-16
AU617342B2 (en) 1991-11-28

Similar Documents

Publication Publication Date Title
US4144237A (en) Synthetic vinblastine and vincristine derivatives
US4737586A (en) Process for the preparation of bis-indolic compounds
JP3606872B2 (en) Antimitotic two-component alkaloid derivatives from periwinkle
CA1042428A (en) Amide derivatives of vlb and leurocristine
CA1341262C (en) A new process of the synthesis of 3&#39;,4&#39;-anhydrovinblastine, vinblastine and vincristine
JPS6314783A (en) 2-Production method of halogenated ergoline derivative
Fukuda et al. Directed C-7 lithiation of 1-(2, 2-diethylbutanoyl) indoles
US5047528A (en) Process of synthesis of vinblastine and vincristine
CA1067073A (en) Amide derivatives of vlb, leurosidine, leurocristine and related dimeric alkaloid
CA1341261C (en) Process for the synthesis of 3&#39;,4&#39;-anhydrovinblastine, vinblastine and vincristine
US4191688A (en) Amides of leurosine, leuroformine, desacetylleurosine and desacetylleuroformine
US4096148A (en) Oxazolidinedione derivatives of Vinca alkaloids
Bourlot et al. A Convenient Synthesis of 1, 2-Dihydro-3H-indol-3-ones and 1, 2-Dihydro-2H-indol-2-ones by Baeyer-Villiger Oxidation
USRE37449E1 (en) Process of synthesis of 3′,4′-anhydrovinblastine, vinblastine and vincristine
Kametani et al. Studies on the syntheses of heterocyclic compounds. 657. Total synthesis of angustine, nauclefine, and gentianine
US4143041A (en) 4&#39;-Deoxyvincristine and related compounds
US4160767A (en) Vinca alkaloid intermediates
IL87347A (en) Process for the synthesis of vinblastine and vincristine
USRE30561E (en) Vinca alkaloid intermediates
EP0001920B1 (en) Vincaleukoblastine derivatives, a process for their preparation, pharmaceutical formulations containing them and the derivatives for use as antimitotic agents
US4430269A (en) 12&#39;-Iodo derivatives of dimeric indole-dihydroindole alkaloids, and process for preparing them
USRE30560E (en) Oxazolidinedione derivatives of Vinca alkaloids
US4159269A (en) Preparation of oxazolidinedione derivatives of Vinca alkaloids
CA1088527A (en) 4&#39;-deoxyvincristine and related compounds
US4175080A (en) Process of producing 5&#39;-hydroxyleurosine and related compounds

Legal Events

Date Code Title Description
MKLA Lapsed